Posted by Michael Wonder on 02 Feb 2023
Calliditas receives conditional marketing authorisation from UK MHRA for Kinpeygo in IgA nephropathy
2 February 2023 - Calliditas Therapeutics today announced that the MHRA of the United Kingdom has granted conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A nephropathy in adults at risk of rapid disease progression with a urine protein to creatinine ratio ≥1.5 g/gram.
